1
|
Chen Y, Li S, Yang Z, Wang T, Yin F, Zhao X, Zhang Y. Value of Bax and Bcl2 expression in peripheral blood mononuclear cells for clinical prognosis of patients with chronic heart failure. Medicine (Baltimore) 2024; 103:e36943. [PMID: 38241555 PMCID: PMC10798729 DOI: 10.1097/md.0000000000036943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 07/28/2023] [Indexed: 01/21/2024] Open
Abstract
To investigate the expression of Bax and Bcl2 protein in peripheral blood mononuclear cells (PBMC) of patients with chronic heart failure (CHF), and to analyze their value for predicting major adverse cardiovascular event (MACE) in CHF patients. A total of 154 fasting venous blood samples from CHF patients were collected in our hospital from January 2017 to June 2019, and they were divided into 2 group according to whether MACE occurred during 3 years follow-up, MACE group and No-MACE group. Levels of Bax and Bcl2 protein expression in PBMC of CHF patients using enzyme-linked immunosorbent assay (ELISA), and then evaluated the predictive power of Bax and Bcl2 expression for MACE using logistic regression analysis and ROC curve. 62 (40.26%) of 154 CHF patients occurred MACE during follow-up, and there were significant differences in age, diabetes, LVEF, LDL-C and NYHA grade between MACE group and No-MACE group. Levels of Bax protein expression in PBMC of CHF patients in MACE group were significantly higher than those in No-MACE group, while levels of Bcl2 protein expression were significantly lower than those in No-MACE group, and Bax and Bcl2 protein levels increased and decreased with NYHA grades in MACE group and No-MACE group, respectively. Results of univariate and multivariate logistic regression analysis showed that Bax (OR, 1.026; 95% CI, 1.003-1.049; P = .027) and Bcl2 levels (OR, 0.952; 95% CI, 0.908-0.998; P = .041) were independent predictive factors for MACE in CHF patients. In addition, Bax and Bcl2 levels could be used to differentiate CHF patients at risk for MACE with an AUC of 0.744 (95% CI: 0.660-0.827) and an AUC of 0.743 (95% CI: 0.667-0.819), respectively. Levels of Bax and Bcl2 protein in PBMC could be used as independent predictive factors for MACE in CHF patients.
Collapse
Affiliation(s)
- Yangang Chen
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| | - Shuiquan Li
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| | - Zhenwen Yang
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| | - Tianlu Wang
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| | - Fahui Yin
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| | - Xiangyu Zhao
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| | - Yong Zhang
- Department of Internal Medicine-Cardiovascular, Liangzhou Hospital of Wuwei City, Wuwei City, Gansu Province, China
| |
Collapse
|
2
|
Maeshima AM, Taniguchi H, Furukawa H, Hattori D, Sasaki H, Makita S, Iwaki N, Fukuhara S, Munakata W, Izutsu K. Diagnostic clues of BCL2-negative, faint, or controversial follicular lymphomas: a study of 103 cases. Hum Pathol 2023; 135:84-92. [PMID: 36702355 DOI: 10.1016/j.humpath.2023.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 01/10/2023] [Accepted: 01/18/2023] [Indexed: 01/25/2023]
Abstract
BCL2 positivity by immunohistochemistry is helpful for the diagnosis of follicular lymphoma (FL); however, a minority of FL cases are BCL2-negative, and the diagnosis is thus challenging. We retrospectively analyzed the incidence, morphology, immunophenotype, and genetic status of BCL21+ (weakly/focally positive by clone 124), BCL20 (negative), and BCL2controversial FLs compared with BCL22+ (strongly positive) FLs to clarify diagnostic clues. In 1068 FL cases, 103 (10%) with BCL21+ (37 cases, 4%), BCL20 (61 cases, 6%), or BCL2controversial (5 cases, 0.5%) were included in the final analysis. BCL21+ and BCL20 FLs tended to have limited stage disease, nodal disease, and grades 3A/3B histology and showed a higher complete response rate than BCL22+ FLs. Among 103 BCL20, BCL21+, or BCL2controversial FL cases, 34 (33%) had a diffuse area composed of CD20-positive small-to medium-sized lymphoid cells, a feature of low-grade B-cell lymphoma. Interfollicular dense CD20-positive cells and interfollicular clusters of CD10-positive cells were observed in 59% and 37% of cases, respectively. In remaining 13/40 cases (33%), BCL2 was converted to BCL22+ by other clones E17/SP66. CD23 and MUM1 were positive in 10/40 (25%) and 1/40 (3%) cases, respectively. IGH/BCL2 fusion and clonality were detected in 6/37 (16%) and 31/34 (91%) cases, respectively. In conclusion, morphological examination of the distribution of CD20-and/or CD10-positive cells and the presence of diffuse area could be used to diagnose FL in most cases. The majority of the remaining FL cases could be diagnosed using other BCL2 clones and clonality analyses.
Collapse
Affiliation(s)
| | - Hirokazu Taniguchi
- Department of Diagnostic Pathology, Tokyo 104-0045, Japan; Department of Pathology and Clinical Laboratory, JR Tokyo General Hospital, Tokyo 151-8528, Japan
| | - Haruhi Furukawa
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Daiki Hattori
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Hirokazu Sasaki
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Shinichi Makita
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Noriko Iwaki
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Suguru Fukuhara
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Wataru Munakata
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Koji Izutsu
- Department of Hematology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| |
Collapse
|